
Dapagliflozin Improves Outcomes in Patients With Chronic Kidney Disease Regardless of Presence of Diabetes
Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.





























